CLDI Stock Overview
A clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Calidi Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.74 |
| 52 Week High | US$137.90 |
| 52 Week Low | US$1.41 |
| Beta | 0.62 |
| 11 Month Change | 9.92% |
| 3 Month Change | -21.69% |
| 1 Year Change | -98.35% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLDI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.7% | -1.0% | 0.2% |
| 1Y | -98.3% | 9.7% | 17.6% |
Return vs Industry: CLDI underperformed the US Biotechs industry which returned 9.7% over the past year.
Return vs Market: CLDI underperformed the US Market which returned 17.6% over the past year.
Price Volatility
| CLDI volatility | |
|---|---|
| CLDI Average Weekly Movement | 21.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CLDI's share price has been volatile over the past 3 months.
Volatility Over Time: CLDI's weekly volatility has decreased from 27% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 41 | Allan Camaisa | www.calidibio.com |
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform.
Calidi Biotherapeutics, Inc. Fundamentals Summary
| CLDI fundamental statistics | |
|---|---|
| Market cap | US$12.39m |
| Earnings (TTM) | -US$29.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs CLDI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLDI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.98m |
| Earnings | -US$29.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -52.2% |
How did CLDI perform over the long term?
See historical performance and comparison